The german s3 guideline prostate cancer: Aspects for the radiation oncologist

Strahlentherapie und Onkologie

Volumn 186, Issue 10, 2010, Pages 531-534

  Wenz, Frederik ^a   Martin, Thomas ^b   Böhmer, Dirk ^c   Martens, Stefan ^d   Sedlmayer, Felix ^e   Wirth, Manfred ^f   Miller, Kurt ^c   Heidenreich, Axel ^g   Schrader, Mark ^h   Hinkelbein, Wolfgang ^c   Wiegel, Thomas ^h  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Group Practice for Radiotherapy and Radiooncology   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Department of Urology   (Germany)

^e Salzburger Landeskliniken ^*  (Austria)

^f UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^g UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^h UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

German S3 guideline; Prostate cancer; Radiation oncology

Indexed keywords

ARTICLE; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MALE; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; METASTASIS; PRACTICE GUIDELINE; PRESCRIPTION; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; S3 GUIDELINE; TECHNICAL AID;

BRACHYTHERAPY; HUMANS; MALE; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL;

EID: 78650173157     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-010-2193-3     Document Type: Article

References (39)

1. Al-Mamgani A, Heemsbergen WD, Peeters ST, Lebesque JV. Role of intensity- modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 2009;73:685-91.
2. Böhmer D, Wenz F, Martin T, et al. Strahlentherapie des Prostatakarzinoms in der neuen S3-Leitlinie Teil 1: Lokal begrenztes und lokal fortgeschrittenes Prostatakarzinom. Urologe A 2010;49:211-5.
3. Bohrer M, Schröder P, Welzel G, et al. Reduced rectal toxicity with ultrasound- based image guided radiotherapy using BAT (B-mode acquisition and targeting system) for prostate cancer. Strahlenther Onkol 2008;184:674-8.
4. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2006;366:572-8.
5. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360: 2516-27.
6. DAmico A, Altschuler M, Whittington R, et al. The use of clinical parameters in an interactive statistical package to predict pathological features associated with local failure after radical prostatectomy for prostate cancer. Clin Perform Qual Health Care 1993;1:219-22.
7. DAmico AV, Chen MH, Renshaw AA, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299:289-95. (Pubitemid 351159365)
8. Dearnaley DP, Sydes MR, Graham JD, et al., RT01 Collaborators. Escalated- dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8:475-87. (Pubitemid 46805903)
9. Deger S, Boehmer D, Roigas J, et al. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. Eur Urol 2005;47:441-8. (Pubitemid 40357885)
10. Demanes DJ, Rodriguez RR, Schour L, et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapys 10-year results. Int J Radiat Oncol Biol Phys 2005;61:1306-16. (Pubitemid 40470411)
11. Galalae RM, Martinez A, Mate T, et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:1048-55. (Pubitemid 38314785)
12. Galalae RM, Martinez A, Nuernberg N, et al. Hypofractionated conformal HDR brachytherapy in hormone naive men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups? Strahlenther Onkol 2006;182:135-41.
13. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02 [Erratum in: J Clin Oncol 2004;22:386]. J Clin Oncol 2003;21:3972-8. (Pubitemid 46606211)
14. Hermesse J, Biver S, Jansen N, et al. A dosimetric selectivity intercomparison of HDR brachytherapy, IMRT and helical tomotherapy in prostate cancer radiotherapy. Strahlenther Onkol 2009;185:736-42.
15. Hoskin PJ, Motohashi K, Bownes P, Bryant L, Ostler P. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol 2007;84:114-20. (Pubitemid 47284526)
16. http://www.krebsgesellschaft.de/download/s3-leitlinie-prostatakarzinom. pdf.
17. Köhler FM, Boda-Heggemann J, Kpper B, et al. Phantom measurements to quantify the accuracy of a commercially available cone-beam CT gray-value matching algorithm using multiple fiducials. Strahlenther Onkol 2009;185:49-55.
18. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67-74. (Pubitemid 350251041)
19. Kumar S, Shelley M, Harrison C, et al. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006;4:CD006019.
20. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:25-33. (Pubitemid 38010333)
21. Lohr F, Fuss M, Tiefenbacher U, et al. Optimierter Einsatz der Strahlentherapie durch IMRT und Präzisionslokalisationsverfahren bei der Behandlung des fortgeschrittenen Prostatakarzinoms. Urologe A 2004;43:43-51. (Pubitemid 38209015)
22. Martin T, Wenz F, Böhmer D, et al. Strahlentherapie des Prostatakarzinoms in der neuen S3-Leitlinie Teil 2: Postoperative Strahlentherapie und Brachytherapie. Urologe A 2010;49:216-20.
23. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990-6. (Pubitemid 46622106)
24. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285-90. (Pubitemid 40470408)
25. Pinkawa M, Piroth MD, Fischedick K, et al. Impact of the target volume (prostate alone vs. prostate with seminal vesicles) and fraction dose (1.8 Gy vs. 2.0 Gy) on quality of life changes after external-beam radiotherapy for prostate cancer. Strahlenther Onkol 2009;185:724-30.
26. Schaefer JW, Welzel G, Trojan L, et al. Long-term health-related quality- of-life outcomes after permanent prostate brachytherapy. Onkologie 2008;31:599-603.
27. Sharkey J, Cantor A, Solc Z, et al. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice. Brachytherapy 2005;4:34-44. (Pubitemid 40292828)
28. Shipley WU, Lu JD, Pilepich MV, et al. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys 2002;54:1302-10. (Pubitemid 35380028)
29. Stephenson CG, Catton CN, DeWeese TL, et al. Predicting the outcome of slavage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:2035-4.
30. Sylvester JE, Blasko JC, Grimm PD, et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys 2003;57:944-52. (Pubitemid 37324111)
31. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009;181:956-62.
32. Van der Kwast TH, Bolla M, Van Poppel H, et al., EORTC 22911. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007;25:4178-86. (Pubitemid 47548556)
33. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301-8.
34. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009;27:2924-30.
35. Wiegel T, Lohm G, Bottke D, et al. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome - results of a retrospective study. Int J Radiat Oncol Biol Phys 2009;73:1009-16.
36. Zelefsky MJ, Wallner KE, Ling CC, et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 1999;17:517-22. (Pubitemid 29075237)
37. Zelefsky MJ, Yamada Y, Kollmeier MA, et al. Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer. Eur Urol 2008;53:1172-9.
38. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional- dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010;28:1106-11.
39. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1233-9. (Pubitemid 41352111)